List of Excipients in Branded Drug CREON

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Atlantic Biologicals Corps	CREON	pancrelipase	17856-1206	CETYL ALCOHOL
Atlantic Biologicals Corps	CREON	pancrelipase	17856-1206	DIMETHICONE
Atlantic Biologicals Corps	CREON	pancrelipase	17856-1206	HYPROMELLOSES
Atlantic Biologicals Corps	CREON	pancrelipase	17856-1206	POLYETHYLENE GLYCOLS
Atlantic Biologicals Corps	CREON	pancrelipase	17856-1206	TRIETHYL CITRATE
Atlantic Biologicals Corps	CREON	pancrelipase	17856-1212	CETYL ALCOHOL
Atlantic Biologicals Corps	CREON	pancrelipase	17856-1212	DIMETHICONE

CREON Excipient Strategy and Commercial Opportunities in Pancrelipase Formulations

Last updated: October 4, 2026

CREON is a high-value pancreatic enzyme replacement therapy built around delayed-release pancrelipase minimicrospheres. Its commercial performance depends on more than lipase, amylase, and protease activity. The formulation must preserve enzyme potency, protect against gastric degradation, disperse predictably in the duodenum, remain stable during storage, and support pediatric administration.

The strongest excipient opportunities are in enteric-coating systems, microencapsulation, moisture control, multiparticulate delivery, taste masking, sprinkle formulations, and lower-cost manufacturing. CREON's formulation complexity creates meaningful barriers for generic developers, but it also creates openings for alternative pancrelipase products using differentiated delivery technologies.

What is CREON and how does its formulation work?

CREON is an oral delayed-release capsule containing pancrelipase, a mixture of porcine-derived lipase, amylase, and protease enzymes. It is approved for exocrine pancreatic insufficiency associated with cystic fibrosis, chronic pancreatitis, pancreatectomy, and other conditions involving inadequate pancreatic enzyme secretion (U.S. Food and Drug Administration [FDA], 2024a).

Each capsule contains enteric-coated pancrelipase minimicrospheres. The capsule shell dissolves in the stomach, while the enteric-coated particles resist gastric acid and release enzymes in the higher-pH environment of the small intestine.

Formulation element	Commercial function
Pancrelipase enzymes	Provides lipase, amylase, and protease activity
Multiparticulate minimicrospheres	Supports dispersion through chyme and more uniform intestinal delivery
Enteric coating	Protects enzymes from gastric acid
Capsule shell	Enables swallowing and sprinkle administration
Buffering and stabilizing excipients	Support potency and physical stability
Moisture-control packaging	Reduces hydrolytic and enzymatic degradation

CREON is sold in multiple lipase strengths, including 3,000, 6,000, 12,000, 24,000, and 36,000 USP lipase units per capsule. Dosing is based primarily on lipase units and is individualized according to meal size, fat content, disease state, age, and clinical response (FDA, 2024a).

What excipients are used in CREON?

The FDA prescribing information identifies a formulation containing several functional excipients. The inactive ingredients include colloidal silicon dioxide, crospovidone, hypromellose phthalate, magnesium stearate, microcrystalline cellulose, talc, and triethyl citrate. The capsule shell contains gelatin and colorants, including titanium dioxide and strength-specific coloring components (FDA, 2024a).

Which CREON excipients are technically important?

Hypromellose phthalate is the principal enteric-coating polymer identified in the label. It is used because it remains substantially intact at low gastric pH and dissolves at a higher intestinal pH.

Triethyl citrate functions as a plasticizer. It improves coating flexibility and reduces brittleness, cracking, and particle-to-particle variability during coating and handling.

Talc can function as an anti-tacking and processing aid in film coating. Magnesium stearate supports manufacturing flow and lubrication. Microcrystalline cellulose provides a structural carrier or processing aid. Crospovidone can contribute to disintegration and dispersion after the enteric coating has dissolved. Colloidal silicon dioxide supports flow and powder handling.

The excipient system is not interchangeable on a simple one-for-one basis. A replacement polymer can alter dissolution pH, coating thickness, residual solvent profile, moisture sensitivity, and enzyme release. A replacement plasticizer can change film flexibility and storage stability. A change in capsule shell composition can affect water activity and enzyme potency.

How does CREON’s excipient strategy protect enzyme activity?

Pancreatic enzymes are proteins and are sensitive to heat, moisture, pH, oxidation, and mechanical stress. The core formulation strategy has four objectives:

1. Protect enzymes during manufacturing and storage.
2. Prevent premature release in the stomach.
3. Release enzyme particles rapidly after gastric emptying.
4. Maintain consistent enzyme activity through the labeled shelf life.

The enteric coating is the central barrier. A coating that dissolves too early can expose enzymes to gastric acid. A coating that dissolves too late can delay enzyme availability beyond the relevant portion of the meal.

Particle size also matters. Small, uniformly distributed particles can mix more effectively with gastric contents and enter the duodenum with the meal. Large or highly variable particles can separate from food and produce less predictable delivery.

The commercial implication is material qualification. Suppliers that can provide consistent pharmaceutical-grade enteric polymers, plasticizers, glidants, and coating systems have a stronger position than suppliers selling commodity excipients without enzyme-specific performance data.

What excipient strategies could improve CREON or competing pancrelipase products?

Enteric-polymer substitution

Potential polymer platforms include hypromellose phthalate, hypromellose acetate succinate, methacrylic acid copolymers, and other pH-dependent coating materials. A replacement may reduce coating weight, accelerate intestinal release, or improve resistance to gastric acid.

A successful substitution must preserve:

• Acid resistance during the relevant gastric residence period.
• Rapid release at intestinal pH.
• Enzyme potency after coating and storage.
• Uniformity across multiple dose strengths.
• Compatibility with sprinkle administration.
• Acceptable residual solvents and elemental impurities.

Plasticizer optimization

Triethyl citrate is a standard pharmaceutical plasticizer, but alternatives such as polyethylene glycol grades, acetylated monoglycerides, or other approved plasticizers may offer different flexibility, permeability, and processing characteristics.

The opportunity is strongest where the developer can reduce coating defects, shorten curing time, lower coating weight, or improve stability under high humidity.

Moisture management

Moisture is a major risk for enzyme products. Commercial opportunities include:

• Higher-barrier blister packs.
• Improved desiccant systems.
• Low-moisture capsule shells.
• Moisture-resistant coating systems.
• Secondary packaging designed for high-humidity markets.
• In-process humidity controls during capsule filling and coating.

Packaging can be as commercially important as the excipient itself. A lower-cost excipient system that requires expensive high-barrier packaging may not improve total cost of goods.

Pediatric and sprinkle formulations

CREON capsules may be opened and the contents sprinkled on a small amount of acidic soft food, subject to label instructions. The enteric-coated particles must remain intact during opening, mixing, swallowing, and short-term contact with food.

Excipient opportunities include:

• Improved particle flow from the capsule.
• Reduced adhesion to food.
• Less grittiness.
• Improved palatability without compromising coating integrity.
• Better dose partitioning for infants and young children.
• Unit-dose sachets or spoonable multiparticulate products.

Pediatric usability is a commercially relevant differentiator because children with cystic fibrosis may require repeated enzyme administration with meals and snacks.

What formulations are protected by CREON’s intellectual property?

CREON’s principal formulation value lies in the combination of pancrelipase enzyme activity with delayed-release multiparticulate delivery. Protection may involve several claim categories:

Claim category	Potential subject matter
Composition	Pancrelipase with specified excipients or coating materials
Formulation	Enteric-coated minimicrospheres or microspheres
Manufacturing	Enzyme loading, coating, curing, drying, and capsule filling
Performance	Acid resistance, dissolution profile, release timing, or activity retention
Method of use	Treatment of exocrine pancreatic insufficiency using specified dosing
Packaging	Moisture-control systems linked to product stability

The relevant patent estate must be assessed against live USPTO records, FDA Orange Book listings, and litigation history. Older pancrelipase patents may have expired while later patents covering manufacturing controls, particle architecture, coatings, or use limitations may remain relevant.

What is the Orange Book status of CREON?

CREON is approved under an FDA new drug application and is associated with the pancrelipase delayed-release capsule product listed in FDA drug databases. The Orange Book is the controlling source for listed patents and regulatory exclusivity associated with the NDA (FDA, 2024b).

A commercial entrant must separate three issues:

1. Whether an Orange Book patent remains listed.
2. Whether the patent remains unexpired.
3. Whether the proposed product can avoid infringement through a Paragraph IV certification, a section viii carve-out, or a different formulation and labeling strategy.

The presence of an Orange Book listing does not itself establish enforceability. Claim scope, prosecution history, terminal disclaimers, obviousness, written description, and infringement exposure remain decisive.

When does CREON lose exclusivity?

CREON's original regulatory approval dates to 2009. Regulatory exclusivity associated with the original NDA is no longer the principal barrier to entry. Market protection now depends primarily on patents, product complexity, manufacturing capability, clinical substitutability, and FDA review of abbreviated applications.

For a generic pancrelipase product, the absence of conventional small-molecule simplicity is important. Pancrelipase is a mixture of enzymes with activity-based specifications rather than a single chemically defined active ingredient. FDA guidance requires control of enzyme identity, potency, impurities, stability, and performance. The agency's product-specific guidance for pancrelipase addresses the analytical and bioequivalence challenges associated with delayed-release enzyme products (FDA, 2018).

Which companies are challenging CREON?

The competitive field includes:

• Generic drug manufacturers developing pancrelipase delayed-release capsules.
• Specialty pharmaceutical companies pursuing pancreatic enzyme replacement products.
• Contract manufacturers with multiparticulate coating capabilities.
• Excipient suppliers developing enzyme-compatible enteric systems.
• Technology companies working on non-porcine or recombinant digestive enzymes.

Generic entry is more difficult than for a conventional oral capsule because an applicant must establish equivalence in enzyme activity, dosage-form performance, and release behavior. A product that matches nominal lipase units but differs materially in particle size, acid resistance, or release kinetics may face regulatory and commercial problems.

Publicly reported market entry should be assessed through FDA ANDA approvals, Paragraph IV notices, district-court filings, and Abbreviated New Drug Application litigation records. Patent litigation involving a pancrelipase product may also concern only selected strengths or formulations rather than the entire product line.

What generic entry risks exist for CREON?

The principal generic-entry scenarios are:

Scenario 1: Direct delayed-release capsule competition

A generic company matches the principal dosage form, enzyme strengths, and release profile. This is the most direct threat to CREON's volume and price.

Scenario 2: Limited-strength entry

A competitor launches selected strengths, such as 12,000, 24,000, or 36,000 lipase units. This can capture high-volume adult prescriptions without reproducing the entire portfolio.

Scenario 3: Sprinkle or pediatric competition

A differentiated multiparticulate product targets children, patients with swallowing difficulty, or caregivers who open capsules. This may compete on usability rather than price.

Scenario 4: Alternative enzyme replacement

A non-porcine or recombinant enzyme product may pursue a new NDA or 505(b)(2) pathway. It could avoid some pancrelipase patent claims but would face clinical, manufacturing, and regulatory requirements.

Scenario 5: Institutional or international substitution

Hospitals, public payers, and foreign markets may adopt lower-cost pancreatic enzyme products even when retail substitution remains limited.

How strong is the CREON patent estate?

The estate is strongest where claims cover product architecture that is difficult to design around, such as:

• Defined multiparticulate size ranges.
• Specific enteric-polymer combinations.
• Enzyme activity retention after processing.
• Release profiles linked to clinical dosing.
• Manufacturing methods required to produce uniform coated particles.

The estate is weaker where claims cover common excipients in isolation. Hypromellose phthalate, triethyl citrate, magnesium stearate, talc, and microcrystalline cellulose are widely used pharmaceutical ingredients. A patent claim directed only to one conventional excipient is more vulnerable to prior-art and obviousness challenges than a claim combining the excipient with a narrowly defined enzyme particle system.

A new entrant can reduce risk through a design-around using a different enteric polymer, coating architecture, particle size distribution, or manufacturing sequence. That approach may create new patentable subject matter but also introduces comparability and stability risk.

What commercial opportunities exist for excipient suppliers?

The most attractive opportunities are not generic commodity sales. They are integrated development packages that include excipients, process parameters, analytical methods, and stability data.

High-value opportunity areas

Opportunity	Buyer value	Main technical barrier
Enzyme-compatible enteric coating	Faster development and reliable gastric protection	Maintaining activity during coating
Low-moisture capsule system	Longer shelf life and fewer potency failures	Shell compatibility and packaging cost
Pediatric multiparticulate platform	Better administration and differentiation	Taste, texture, and dose uniformity
High-throughput coating process	Lower cost per capsule	Uniformity across multiple strengths
Alternative non-porcine formulation	Religious, ethical, and supply-chain access	Enzyme performance and clinical validation
Unit-dose sprinkle packaging	Improved adherence and caregiver convenience	Moisture protection and dose handling
Analytical release package	Reduced development burden	Correlating in vitro release with clinical performance

Excipient companies can also license proprietary coating systems to generic manufacturers. The strongest licensing proposition would combine freedom-to-operate analysis, pilot-scale coating data, enzyme activity retention, dissolution profiles, and regulatory support.

How does CREON compare with other pancreatic enzyme replacement products?

CREON competes with other pancreatic enzyme replacement therapies, including Zenpep, Pancreaze, Pertzye, and Viokace in the United States. These products also rely on enzyme activity, delayed release, and dose titration, but their excipient systems, particle designs, capsule strengths, and regulatory histories differ.

Product	Active ingredient	Dosage-form focus	Commercial differentiation
CREON	Pancrelipase	Delayed-release capsules and minimicrospheres	Broad strength range and established market position
Zenpep	Pancrelipase	Delayed-release capsules	Competing enzyme replacement portfolio
Pancreaze	Pancrelipase	Delayed-release capsules	Alternative delayed-release product
Pertzye	Pancrelipase	Delayed-release capsules	Formulation and dosing differentiation
Viokace	Pancrelipase	Non-enteric-coated tablets used with a proton-pump inhibitor	Different gastric protection strategy

Viokace demonstrates the strategic importance of formulation architecture. Because it is not enteric-coated, acid suppression is required to reduce gastric enzyme degradation. This creates a different excipient and prescribing model from CREON's acid-resistant multiparticulate system.

What manufacturing and IP barriers affect commercial entry?

Manufacturing is a major barrier. Developers need validated methods for:

• Enzyme blending without activity loss.
• Uniform loading of microspheres.
• Controlled enteric coating.
• Low-temperature drying.
• Moisture-controlled capsule filling.
• Strength-specific potency testing.
• Dissolution testing at gastric and intestinal pH.
• Stability testing under accelerated and long-term conditions.

The analytical burden is also substantial. Lipase, amylase, and protease activities must be measured separately. Potency is not established solely by mass balance because enzymatic activity can decline without an obvious change in composition.

For manufacturers, the most defensible process advantages are narrow operating windows that improve coating uniformity, reduce enzyme degradation, and produce reproducible release across strengths. These process controls can support both patent protection and regulatory differentiation.

What FDA regulatory pathway applies to new CREON competitors?

A conventional delayed-release pancrelipase product may pursue an ANDA if it meets FDA requirements for sameness, bioequivalence, quality, and labeling. The product-specific guidance for pancrelipase is central to development planning (FDA, 2018).

A materially different product may require an NDA or 505(b)(2) application. This is more likely where the applicant changes the enzyme source, delivery technology, dosage form, indication, or clinical use. A recombinant enzyme platform would generally require a full regulatory strategy rather than assuming that an abbreviated pathway is available.

FDA review will focus on:

• Enzyme source and characterization.
• Potency and activity assays.
• Impurity controls.
• Particle size distribution.
• Acid resistance.
• Intestinal release.
• Stability.
• Dose proportionality across strengths.
• Labeling and administration instructions.

What licensing and partnership opportunities exist?

Commercial partnerships can be structured around three assets:

1. A coating or multiparticulate platform.
2. A generic or 505(b)(2) product candidate.
3. A supply agreement for specialized excipients or coated enzyme intermediates.

Potential counterparties include enzyme manufacturers, generic pharmaceutical companies, excipient suppliers, contract development and manufacturing organizations, and specialty gastrointestinal companies.

The most valuable deal terms are likely to involve territory, strength coverage, formulation ownership, regulatory responsibility, minimum purchase volumes, manufacturing technology transfer, and rights to improvements. An excipient supplier with a validated platform may obtain stronger economics by licensing a complete formulation and process rather than selling individual ingredients.

Key Takeaways

• CREON's commercial performance depends on multiparticulate delivery, enteric protection, enzyme stability, and moisture control.
• Hypromellose phthalate and triethyl citrate are important components of the labeled excipient system.
• Excipient replacement is technically possible but requires preservation of acid resistance, intestinal release, enzyme activity, and sprinkle performance.
• The strongest commercial opportunities are integrated coating platforms, pediatric multiparticulate systems, moisture-control packaging, and enzyme-compatible manufacturing processes.
• Generic entry is constrained by pancrelipase's biological complexity, activity-based potency testing, formulation comparability, and manufacturing controls.
• Conventional excipients are weak standalone patent assets. Claims combining excipients with defined particle architecture, release behavior, or manufacturing parameters are more defensible.
• CREON competes with Zenpep, Pancreaze, Pertzye, and Viokace, with product differences centered on release design, dosing, and administration.
• FDA Orange Book listings, live patent status, Paragraph IV filings, and ANDA approvals determine the current legal and commercial entry risk.

FAQs

Can CREON excipients be replaced without conducting new clinical trials?

A formulation change may avoid new clinical trials if the product remains within an accepted abbreviated pathway and demonstrates pharmaceutical equivalence, bioequivalence, activity, dissolution, and stability. A material change in enzyme source or release behavior can require a more extensive regulatory package.

Which excipient is most important for CREON’s delayed release?

Hypromellose phthalate is the key identified enteric polymer. Its performance depends on coating thickness, plasticizer content, curing conditions, particle size, and storage humidity.

Is there a market for non-porcine pancreatic enzyme products?

Yes. Non-porcine products could address religious, ethical, supply-chain, and patient-acceptance considerations. The main barriers are equivalent enzyme activity, scalable production, stability, clinical validation, and regulatory classification.

Can a generic manufacturer use the same CREON excipients?

Use of the same excipients does not by itself establish infringement or regulatory equivalence. The relevant analysis includes excipient grade, amount, process, particle architecture, coating structure, release profile, and patent claim scope.

What is the most attractive near-term commercial opportunity around CREON?

The strongest near-term opportunity is a validated enteric-coated multiparticulate platform that improves coating efficiency, moisture stability, pediatric administration, or manufacturing cost while maintaining enzyme activity and FDA-compliant release performance.

References

AbbVie Inc. (2024). 2023 annual report. https://www.abbvie.com

U.S. Food and Drug Administration. (2018). Pancrelipase delayed-release capsules: Product-specific guidance for industry. https://www.fda.gov

U.S. Food and Drug Administration. (2024a). CREON (pancrelipase) delayed-release capsules prescribing information. https://www.accessdata.fda.gov

U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov